TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Green Tea Extract on Arterial Stiffness in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of T2DM~* Fasting plasma glucose \>126 and \<250 mg/dl at the time security~* Metformin monotherapy or with glibenclamide added~* Written informed consent~Exclusion Criteria:~* Hypertention~* Treated with insulin~* Use of antioxidant suplements or products with caffeine~* Woman pregnant or breastfeeding~* Untreated tyroid disease~* Total colesterol \>400mg/dl~* Triglycerides \>400mg/dl~* Liver enzimes (alt and ast) more tan twice the normal range~* Glomerular filtration rate \<60ml/min (Cockcroft-Gault)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Green tea extract (Type: EXPERIMENTAL): Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
- Placebo (Type: PLACEBO_COMPARATOR): Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Main inclusion criteria:~* Written informed consent~* Asthma diagnosis for at least 6 months~* Prebronchodilator FEV1 45-90% of the predicted value~* Demonstration of reversible airway obstruction~* Stable asthma on the same regular treatment for at least 4 weeks before the study~* Non-smoker for at least 6 months before the study~Main exclusion criteria~* Respiratory infection within 4 weeks before the study~* Smoking history of more than 10 pack-years~* Other severe chronic respiratory disease than asthma~* Concurrent illness that would interfere with the interpretation of the study results or constitute a health risk for the patient if he/she takes part in the study~* Corrected QT interval \> 450 ms in males or \> 470 ms in females~* Abnormal serum potassium value or other clinically significant laboratory finding~* Systolic blood pressure over 180 mmHg and/or diastolic blood pressure over 100 mmHg~* Treatment with a long-acting β2-agonist, a xanthine-derivative, a β-blocker or with a corticosteroid (other than inhaled) within 4 weeks before the study~* Use of drugs that prolong QT-interval~* Women who are pregnant, breast-feeding or without reliable contraception~* Participation in another clinical drug study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh (Type: EXPERIMENTAL): Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
- Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh (Type: EXPERIMENTAL): Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
- Symbicort Turbuhaler 320/9 ug/inhalation 4 inh (Type: EXPERIMENTAL): Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh
- Symbicort Turbuhaler 320/9 ug/inhalation 1 inh (Type: EXPERIMENTAL): Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification).~* Age from18 to 59 years, eligible for transplant.~* Patient not previously treated.~* Baseline FDG-PET Scan (PET0) performed before any treatment with at least one hypermetabolic lesion.~* Index prognostic factors (IPI) 2 or 3.~* With a minimum life expectancy of 3 months.~* Negative HIV, HBV and HCV serologies £ 4 weeks (except after vaccination).~* Having previously signed a written informed consent.~Exclusion Criteria:~* Any other histological type of lymphoma.~* Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.~* Central nervous system or meningeal involvement by lymphoma.~* Contra-indication to any drug contained in the chemotherapy regimens.~* Poor renal function (creatinin level \>150 mmol/l), poor hepatic function (total bilirubin level \>30 mmol/l, transaminases \>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration.~* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ)cervical carcinoma.~* Any serious active disease (according to the investigator's decision).~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy.~* Pregnant or lactating women or women of childbearing potential not currently practicing an adequate method of contraception~* Adult patient under tutelage.~* Impossibility to performed a baseline PET scan (PET0) before randomization and treatment beginning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- R-CHOP-14 (Type: EXPERIMENTAL): R-CHOP14 induction regimen
- R-ACVBP14 (Type: EXPERIMENTAL): R-ACVBP14 induction regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MTX Discontinuation and Vaccine Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females \> 18 years at time of consent~* Have a diagnosis of RA per ACR criteria~* Must understand and voluntarily sign an informed consent form including writing consent for data protection~* Stable doses of methotrexate over the preceding 6 weeks~Exclusion Criteria:~* Pregnant or lactating females~* Previous anaphylactic response to vaccine components or to egg.~* Acute infection with T \>38°C at the time of vaccination~* History of Guillain-Barre syndrome or demyelinating syndromes~* Previous vaccination with any live vaccine 4 weeks before or any inactivated vaccine 2 weeks before the study~* Blood transfusion within 6 months~* Active rheumatoid arthritis necessitating a recent change in the drug regimen~* Any other rheumatic disease such as systemic lupus erythematosus, mixed connective tissue disease, dermatomyositis/polymyositis, and vasculitis except for secondary Sjogren's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (No MTX Hold before Vaccination) (Type: EXPERIMENTAL): Group 1 will continue MTX
- Group 2 (MTX hold 4 Weeks before vaccination) (Type: EXPERIMENTAL): Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
- Group 3 (MTX hold 2 Weeks before Vaccination) (Type: EXPERIMENTAL): Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
- Group 4 (MTX hold on Day of Vaccination) (Type: EXPERIMENTAL): Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer of the ovaries, fallopian tube or abdominal lining has come back after more than 6 months from the last platinum based chemotherapy treatment.~* Disease must be detected by CT or CA125 level must be elevated or cancerous ascites must be present.~* History of at least one therapy of platinum based chemotherapy.~Exclusion Criteria:~* Participation in another experimental drug study~* Heart disease or high blood pressure~* History of a stroke within the past 6 months~* Vascular disease, or bleeding problems~* Brain cancer~* Major Surgical Procedure within 28 days prior to start date~* Minor surgical procedures within 7 days prior to start date~* Pregnant or lactating~* Abdominal or bowel problems like bleeding~* History of abdominal fistula, GI perforation or Intra-abdominal abscess~* Serious, non-healing wound, ulcer or bone fracture~* Acute hepatitis~* Active infections requiring antibiotics~* Inability to comply with study or follow up procedures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine/carboplatin/bevacizumab (Type: EXPERIMENTAL): A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Therapy-naive patients with histologically confirmed diagnosis of a locally inoperable or metastasized well-differentiated neuroendocrine tumor of the midgut~* curative surgery impossible~* two-dimensional tumor formation assessable by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)~* Age ≥ 18~* Karnofsky-index \> 60~* written informed consent~* proliferation index for Ki67~Exclusion Criteria:~* hypersensitivity to octreotide~* poorly differentiated or small cell neuroendocrine tumors~* primary tumor outside of the midgut~* prior treatment with somatostatin-analogue \> 4 weeks~* prior treatment with alpha-interferon, chemotherapy, or chemoembolisation~* participation in any other clinical trial~* pregnancy or lactation~* no secondary malignancy in anamnesis; with the exception of patients without any manifestation of the secondary malignancy (without relapse) after curative therapy within the last five years~* severe decompensated organ malfunction (heart-, liver- insufficiency)~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octreotide LAR (Long Acting Release) (Type: EXPERIMENTAL): Octreotide LAR 30 mg intramuscularly every 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - Sodium chloride intramuscularly every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Breast cancer and negative lymph nodes~2. HLA-A2+ and/or HLA-A3+ to receive the vaccine. HLA-A2-, HLA-A3- patients will be eligible to be included in the control group.~3. Immunologically intact with a good performance status (defined below).~4. Without evidence of disease.~5. Patients may enroll while receiving appropriate hormonal therapy for their disease.~6. Completion of all standard first-line therapies (but may still be on hormonal therapy)~Exclusion Criteria:~1. HLA-A2- and/or HLA-A3- patients will not be vaccinated~2. Anergic by the Mantoux panel of recall antigens~3. Receiving immunosuppressive therapy~4. In poor health (Karnofsky \<60%, ECOG \>2)~5. Tbili \>1.5 mg/dL and creatinine\>2 mg/dL~6. Pregnancy (urine HCG)~7. Active metastatic disease~8. Involved in other experimental protocols (unless approval is first obtained by the other study PI)~9. Refusal of standard therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine (Type: EXPERIMENTAL): HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
- Control/observation (Type: NO_INTERVENTION): HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nebulised Hypertonic Saline in Children and Young People With Neuromuscular Disease and Cerebral Palsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children with Neuromuscular disease or Cerebral Palsy who have been on treatment with nebulised Hypertonic Saline for at least 12 months.~Exclusion Criteria:~* Children also diagnosed with cystic fibrosis.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: None

Study Arms:
- Before treatment (Type: None): Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)
- After treatment (Type: None): Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dexmedetomidine and Propofol-Remifentanil Conscious Sedation for Awake Craniotomy for Tumor Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients more than 18 years of age.~* ASA score I, II and III.~* Patients scheduled to undergo awake craniotomy for elective tumor resection.~Exclusion Criteria:~* Patients with allergies to the drugs being used.~* Patients who are pregnant.~* Patients with alcohol or substance abuse.~* Patients who are not able to understand the instructions for an awake craniotomy and questions regarding intra-operative pain, and post-operative satisfaction.~* Lack of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol-Remifentanil (Type: ACTIVE_COMPARATOR): Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
- Dexmedetomidine (Type: EXPERIMENTAL): Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, between 18 and 55 years of age~2. A clinical diagnosis of schizophrenia with a minimum duration of 1 year~3. Has predominant negative symptoms according to predefined study criteria~4. The main background antipsychotic with which the subject is being treated must be one of the antipsychotics listed below:~   * Aripiprazole~  * Aripiprazole long-acting injectables:~     * Abilify Maintena®~    * Aristada®~  * Risperidone~  * Risperidone long-acting injection~  * Olanzapine~  * Lurasidone~  * Cariprazine~  * Brexpiprazole~  * Asenapine~Exclusion Criteria:~1. Patient has a psychiatric disorder other than schizophrenia~2. A urine drug screen (UDS) result at Baseline that indicates the presence of any tested prohibited substance of potential abuse, except marijuana~   a. Patients with a result indicating the presence of marijuana are permitted if they agree to abstain from marijuana use during the study and the medical monitor approves the subject's participation~3. Patient has current evidence of a serious and/or unstable psychiatric, neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program~4. Patient has had a myocardial infarction in the last six months~5. Patient has a family or personal history or symptoms of long QT syndrome~6. Patient has been hospitalized due to inadequate family support or care at the patient's primary residence, during the 8 weeks prior to screening~Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Pimavanserin (Type: EXPERIMENTAL): Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, taken as two tablets + background antipsychotic, once daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have participated in and completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402 (Kinect 4) Phase 3 study.~* Participants of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently throughout the study and until 30 days after the last dose of valbenazine.~* If using maintenance medication(s) for schizophrenia or schizoaffective disorder, mood disorder, or other conditions, be on stable doses.~* Be in general good health.~* Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.~Exclusion Criteria:~* Have an active, clinically significant unstable medical condition within 1 month prior to screening.~* Have a known history of substance dependence, substance (drug) or alcohol abuse.~* Have a significant risk of suicidal or violent behavior.~* Have a known history of neuroleptic malignant syndrome.~* Have a known history of long QT syndrome or cardiac arrhythmia.~* Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).~* Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than valbenazine) during the study.~* Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.~* Have an allergy, hypersensitivity, or intolerance to tetrabenazine.~* Are currently pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Valbenazine (Type: EXPERIMENTAL): Fixed dose of valbenazine administered once daily for up to 72 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Korean Post-marketing Surveillance for Orencia®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Patients must be diagnosed with: Adult Rheumatoid arthritis (RA): adult patients with moderate-to-severe active RA~Or~* Juvenile idiopathic RA: juvenile patients aged 6 years and older with moderate-to-severe active RA~Exclusion Criteria:~* Children aged \<6 years~* Pregnant or lactating women~* Patients who are participating in another study~* Patients known to be hypersensitive to the active component of the surveillance drug or any other component of the surveillance drug~* Patients who had a positive tuberculosis screening test but were not treated with standard therapy before participating in the study~* Patients who have a positive hepatitis virus test~* Patients who were given a live vaccine concurrently with the surveillance drug or are expected to be given a live vaccine again within 3 months after discontinuation of the surveillance drug

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with active rheumatoid arthritis (Type: None): Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete